Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > It Was Just A Typo

<< Previous

Bullboard Posts

Next >>

Comment by itntdfon Jun 27, 2024 4:30pm

75 Views

Post# 36109647

RE:RE:RE:RE:RE:RE:It Was Just A Typo

when one appoints someone else to be their poa, that is a big deal. when the person is appointed "in error", that's an even bigger deal. to not correct a legal document and remove a legal poa whom they say was appointed in error and that it was just a typo, is also a big deal, not to mention sloppy as hell.

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter